Zentalis Pharmaceuticals Reports Q3 2025 Financial Results

Tip Ranks
2025.11.10 21:36
portai
I'm PortAI, I can summarize articles.

Zentalis Pharmaceuticals (ZNTL) reported its Q3 2025 financial results, showcasing progress in its DENALI Phase 2 trial for azenosertib, with topline data expected by late 2026. The company has $280.7 million in cash, supporting operations until late 2027, and has reduced R&D expenses. Analysts rate ZNTL stock as a Buy with a $10.00 price target, though Spark's AI Analyst considers it Neutral due to financial challenges and weak momentum. Zentalis focuses on developing azenosertib for aggressive cancers, despite facing significant risks.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Zentalis Pharmaceuticals ( (ZNTL) ) has shared an announcement.

Zentalis Pharmaceuticals reported its third quarter 2025 financial results, highlighting significant progress in its DENALI Phase 2 trial for azenosertib, which remains on track with topline data expected by the end of 2026. The company is financially robust with $280.7 million in cash, supporting operations into late 2027, and has reduced its research and development expenses compared to the previous year, reflecting a strategic focus on advancing azenosertib’s development, potentially leading to accelerated FDA approval.

The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.

Spark’s Take on ZNTL Stock

According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.

Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.

To see Spark’s full report on ZNTL stock, click here.

More about Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing azenosertib, a potentially first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and other tumor types. The company is leveraging its expertise to explore additional opportunities for azenosertib beyond PROC.

Average Trading Volume: 762,810

Technical Sentiment Signal: Strong Sell

Current Market Cap: $92.33M

Learn more about ZNTL stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer